A pilot study of pharmacokinetically guided dose management of capecitabine in CRC patients.

@article{Makihara2012APS,
  title={A pilot study of pharmacokinetically guided dose management of capecitabine in CRC patients.},
  author={Katsuya Makihara and Hideyuki Mishima and Sayaka Azuma and Kazuyo Matsuyama and Katsuya Komori and Hiroko Hasegawa and Masayoshi Yasui and Masakazu Ikenaga and Toshimasa Tsujinaka},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 4_suppl},
  pages={510}
}
510 Background: Pharmacokinetically (PK) guided dose adjustment of 5-fluorouracil (5-FU) has been reported better than body surface area based dosing of 5-FU. On the other hand, few articles have been reported about PK guided dose management of oral drug chemotherapy. The aim of this study is to assess the possibility of pharmacokinetically guided dose management of capecitabine with a nanoparticle antibody-based immunoassay for 5-FU (My5-FUR assay). METHODS Colorectal cancer patients… CONTINUE READING
BETA